Total Facial Autologous Fat Grafting for Treating Skin Manifestations in Scleroderma

Ariel Berl*, Ofir Shir-az, Noa Perk, Abraham Levy, Yair Levy, Avshalom Shalom

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Systemic sclerosis (SSc) or scleroderma, is a rare, systemic autoimmune connective tissue disease that can cause fibrosis of cutaneous tissue and visceral organs. Facial involvement can have a deleterious effect on patients’ function, cosmetic appearance and quality of life. This study describes our experience and results with total facial autologous fat grafting for treating scleroderma. It includes 14 women and 3 men with SSc, at an average age of 51.3 years who underwent 32 autologous fat grafting surgeries between 2017–2022. The surgical technique is further described and demographic and surgical data, including preoperative and postoperative measurements were analyzed. Patients who had multiple surgeries ultimately received grafts with twice the volume of fat than in the first procedure. The oral opening increased an average of 33%. All patients reported improvement in quality of life and were very satisfied with the aesthetic outcomes. The use of autologous fat grafting to treat SSc patients successfully increased oral openings and improved facial manifestations. The procedure is reproducible, safe and leads to improvement in facial manifestations and patients’ quality of life. It can be repeated over time to preserve or enhance the results.

Original languageEnglish
Article number1997
Issue number12
StatePublished - Dec 2022


  • adipose-derived stem cells
  • autologous fat grafting
  • scleroderma
  • systemic sclerosis (SSc)


Dive into the research topics of 'Total Facial Autologous Fat Grafting for Treating Skin Manifestations in Scleroderma'. Together they form a unique fingerprint.

Cite this